CHARACTERIZATION OF BIVALIRUDIN USE IN COVID-19 EXTRACORPOREAL MEMBRANE OXYGENATION PATIENTS

ABSTRACT

B Introduction: b The Extracorporeal Life Support Organization (ELSO) recommends that patients requiring extracorporeal membrane oxygenation (ECMO) receive systemic anticoagulation to mitigate the thrombotic potential of the extracorporeal device. B Methods: b This retrospective cohort study included patients with COVID-19 requiring ECMO who received bivalirudin for anticoagulation from April 1, 2020 to April 19, 2021. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)